IPOGrid
0002078148
IPO filing research
Zoar Ltd
Pharmaceutical Preparations · ZOAR
ipo
amended
NYSE American
F-4/A
Zoar Ltd IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: F-4/A on 2026-10-05. Current deal snapshot: exchange NYSE American.
Filing Timeline
SEC EDGAR
F-4/A
amended
F-4/A
Pre-IPO filing captured from the SEC submission timeline.
First tracked pre-IPO filing for this issuer.
Range $0.40 to $7.11
Common Stock · Use of proceeds to complete the business combination and for general corporate purposes · Flags cayman_holding_company · Underwriters Revere Securities, LLC
2026-10-05 · 0001493152-26-045654
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
First tracked pre-IPO filing for this issuer.
2026-09-17 · 0001493152-26-042978
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows DRS in the pre-IPO sequence.
2026-09-15 · 0001493152-26-042644
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
First tracked pre-IPO filing for this issuer.
2026-09-15 · 0001493152-26-042640
F-4
filed
F-4
Pre-IPO filing captured from the SEC submission timeline.
Follows DRS/A in the pre-IPO sequence.
Price $3.00 · 1,500,000 shares
Common Stock · Exchange NYSE American · Ticker IBO · Warrants to purchase shares at 125% of the public offering price · Flags warrants · Underwriters Revere Securities, LLC.
2026-09-10 · 0001493152-26-042161
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
2026-08-18 · 0001493152-26-038849
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
2026-06-26 · 0001493152-26-030355
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS filing.
Zoar Ltd's current filing highlights financial performance and risk factors. For the year ended March 31, 2025, revenue from 10 customers totaled 32% (vs. 51% in 2024), with no single customer exceeding 10%. Accounts receivable geographic concentration decreased to 65% (Africa, India, Middle East) from 75% in 2024. The company maintains multiple suppliers but faces risks from limited provider availability. Recent accounting standard adoptions (ASU 2023-07, ASU 2023-09) and pending implementation of ASU 2024-03 are noted. No allowance for credit losses was recorded due to historical payment patterns.
2026-03-02 · 0001493152-26-008409
DRS
filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
The filing presents financial data for Zoar Ltd as of 2025-09-16, including balance sheet details, income statements, and unaudited pro forma combined financial information. Key financial metrics show total assets of $19.06M, liabilities of $26.44M, and a stockholders' deficit of $7.38M. The document highlights a significant net loss of $14.35M for the three months ended June 30, 2025, with operating losses and interest expenses impacting profitability. Pro forma adjustments reflect a Business Combination, but specific details about Zoar Ltd's pre-IPO changes remain unclear.
2025-09-16 · 0001493152-25-013600
Comparable Deals
20 comparable deals
Healthcare & BiotechLast 18 months
Only 0 strict matches; expanded to 20 using nearest neighbors.
Showing top 8 by similarity.
ADARx Pharmaceuticals, Inc.
ADRX
same SICrecent IPO
Vogenx, Inc.
VOGX
same SICrecent IPO
BlossomHill Therapeutics, Inc.
BLSM
same SICrecent IPO
Latigo Biotherapeutics, Inc.
LTGO
same SICrecent IPO
Braveheart Bio, Inc.
BRVE
same SICrecent IPO
Apnimed, Inc.
APMD
same SICrecent IPO
Kardigan, Inc.
KARD
same SICrecent IPO
Parabilis Medicines, Inc.
PBLS
same SICrecent IPO
Recent News
No recent news stored for this issuer.